Effects of valsartan and 17β-estradiol on the oxidation of low-density lipoprotein in vitro

Coronary Artery Disease

Volumn 11, Issue 4, 2000, Pages 347-349

  Seeger, Harald ^a   Mueck, Alfred O ^a   Lippert, Theodor H ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Section of Clinical Pharmacology   (Germany)

Author keywords

17 estradiol; Oxidation of low density lipoprotein; Valsartan

Indexed keywords

CUPRIC CHLORIDE; ESTRADIOL; LOW DENSITY LIPOPROTEIN; VALSARTAN;

ARTICLE; CARDIOVASCULAR DISEASE; ESTROGEN DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; OXIDATION; POSTMENOPAUSE; PRIORITY JOURNAL; SPECTROMETRY;

ANTIHYPERTENSIVE AGENTS; CHOLESTEROL, LDL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; HUMANS; POSTMENOPAUSE; TETRAZOLES; VALINE;

EID: 0034118501     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200006000-00008     Document Type: Article

References (12)

1. 1 Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses Health Study. N Engl J Med 1991; 325:756-762.
2. 2 Lippert TH, Mueck AO, Ginsburg J (editors). Sex steroids and the cardiovascular system. London: Parthenon Publishing Group; 1997.
3. 3 Seeger H, Mueck AO, Lippert TH. Effect of estradiol metabolites on the susceptibility of low density lipoprotein to oxidation. Life Sci 1997; 61:865-868.
4. 4 Maziere C, Auclair M, Ronveaux M-F, Salmon S, Santus R, Maziere J-C. Estrogens inhibit copper and cell-mediated modification of low density lipoprotein. Atherosclerosis 1991; 89:175-182.
5. 5 Rifici VA, Chong L, Khachadurian AK. Inhibition of low density lipoprotein oxidation by 17 beta estradiol. Clin Res 1992; 40:208A.
6. 6 Oettel M, Dören M, Hübler D, Römer W, Schröder J, Schumann I, et al. Freie Radikale und Sexualhormone. J Menopause 1995; 3:21-28.
7. 7 Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Rad Res Commun 1989; 6:67-75.
8. 8 Parthasarathy S, Steinberg D, Witzum JL. The role of oxidized low-density lipoprotein in the pathogenesis of atherosclerosis. Annu Rev Med 1992;43:219-225.
9. 9 Galle J, Mülsch A, Busse R, Bassenge E. Effects of native and oxidized low density lipoproteins on formation and inactivation of endothelium-derived relaxing factor. Arterioscl Thromb 1991; 11:198-203.
10. 10 Horio T, Kohno M, Yasunari K, Murakawa K, Yokokawa K, Ikeda M, et al. Stimulation of endothelin-1 release by low-density and very low density lipoproteins in cultured human endothelial cells. Atherosclerosis 1993; 101:185-190.
11. 14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997; 27:59-71.
12. 12 Sack MM, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994; 343:269-270.